November 1st 2024
In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.
Pharma and Biotech Markets: Mostly Sunny, But An Uncertain Forecast
May 9th 2017Pharm Exec's Editorial Advisory Board member, Peter Young, cover a summary of the strategic issues facing the biopharma industry, but goes on to tell the story of what happened last year and this first quarter in terms of the stock market, M&A and financing (including IPOs) activity, where it is headed, and the implications for senior management.
Region in Reform? Access Pains and Gains in Latin America
February 28th 2017Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry
Supply Chain Integration or Bust… or Both
February 12th 2016The recent formation of three mega supply-chain purchasing groups (Walgreen’s-AllianceBoots-AmerisourceBergen-Rite-Aid, McKesson-Celesio, CVS-Cardinal) denotes a shift in the balance of power between wholesalers, chains, generic pharmaceutical companies and branded pharma companies.